The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Non-alcoholic steatohepatitis: From cell biology to clinical practice
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Design and validation of a histological scoring system for nonalcoholic fatty liver disease†
Kleiner, D. E., Brunt, E. M., Van Natta, M., Behling, C., Contos, M. J., Cummings, O. W., Ferrell, L. D., Liu, Y., Torbenson, M. S., Unalp‐Arida, A., et al. (2005) · Hepatology · doi:10.1002/hep.20701 · Cited by 10,791 · cited 1×
“[20] designed and validated a histological feature scoring system that addresses the full spectrum of lesions of NAFLD and proposed a NAFLD activity score (NAS) for use in clinical trials.”
MethodIncreased oxidative stress in obesity and its impact on metabolic syndrome
Furukawa, S., Fujita, T., Shimabukuro, M., Iwaki, M., Yamada, Y., Nakajima, Y., Nakayama, O., Makishima, M., Matsuda, M., & Shimomura, I. (2004) · Journal of Clinical Investigation · doi:10.1172/jci21625 · Cited by 5,508 · cited 3×
“Circulating adiponectin levels are reduced in obesity, insulin resistance and T2DM [88] due, at least in part, to suppression of its synthesis by TNFa [87] and possibly to increased oxidative stress [67].”
BackgroundNonalcoholic Fatty Liver Disease
Angulo, P. (2002) · New England Journal of Medicine · doi:10.1056/nejmra011775 · Cited by 5,228
Yamauchi, T., Kamon, J., Waki, H., Terauchi, Y., Kubota, N., Hara, K., Mori, Y., Ide, T., Murakami, K., Tsuboyama-Kasaoka, N., et al. (2001) · Nature Medicine · doi:10.1038/90984 · Cited by 4,915
Steatohepatitis: A tale of two “hits”?
Day, C. P., & James, O. F. W. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70599-2 · Cited by 4,285
Self-citationNonalcoholic Steatohepatitis: A Proposal for Grading and Staging The Histological Lesions
Brunt, E. M., Janney, C. G., Di Bisceglie, A. M., Neuschwander-Tetri, B. A., & Bacon, B. R. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01377.x · Cited by 3,907
Endoplasmic Reticulum Stress Links Obesity, Insulin Action, and Type 2 Diabetes
Özcan, U., Cao, Q., Yilmaz, E., Lee, A.-H., Iwakoshi, N. N., Özdelen, E., Tuncman, G., Görgün, C., Glimcher, L. H., & Hotamisligil, G. S. (2004) · Science · doi:10.1126/science.1103160 · Cited by 3,844
Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.
MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., & MCCULLOUGH, A. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70506-8 · Cited by 3,345
Fadok, V. A., Bratton, D. L., Konowal, A., Freed, P. W., Westcott, J. Y., & Henson, P. M. (1998) · Journal of Clinical Investigation · doi:10.1172/jci1112 · Cited by 3,166 · cited 3×
“Hepatocyte apoptosis leads to fibrogenesis following the ingestion of apoptosing hepatocytes by Kupffer cells and HSC themselves which subsequently release TGFb capable of activating HSC [91,92].”
BackgroundLudwig, J., Viggiano, T. R., McGill, D. B., & Ott, B. J. (1980) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(24)00530-5 · Cited by 2,903
Cited by
Nonalcoholic Fatty Liver Disease: Pathology and Pathogenesis
Tiniakos, D. G., Vos, M. B., & Brunt, E. M. (2010) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-121808-102132 · Cited by 870
Role of Kupffer cells in host defense and liver disease
Bilzer, M., Roggel, F., & Gerbes, A. L. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01342.x · Cited by 856
Li, Z., Agellon, L. B., Allen, T. M., Umeda, M., Jewell, L., Mason, A., & Vance, D. E. (2006) · Cell Metabolism · doi:10.1016/j.cmet.2006.03.007 · Cited by 752
Molecular pathways of nonalcoholic fatty liver disease development and progression
Bessone, F., Razori, M. V., & Roma, M. G. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2947-0 · Cited by 610
Systematic review of risk factors for fibrosis progression in non-alcoholic steatohepatitis
Argo, C. K., Northup, P. G., Al-Osaimi, A. M. S., & Caldwell, S. H. (2009) · Journal of Hepatology · doi:10.1016/j.jhep.2009.03.019 · Cited by 552
Best practice guidance for the diagnosis and management of cystic fibrosis-associated liver disease
Debray, D., Kelly, D., Houwen, R., Strandvik, B., & Colombo, C. (2011) · Journal of Cystic Fibrosis · doi:10.1016/s1569-1993(11)60006-4 · Cited by 432
Interleukin-17 exacerbates hepatic steatosis and inflammation in non-alcoholic fatty liver disease
Tang, Y., Bian, Z., Zhao, L., Liu, Y., Liang, S., Wang, Q., Han, X., Peng, Y., Chen, X., Shen, L., et al. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04471.x · Cited by 294
Lactobacillus rhamnosus GG protects against non-alcoholic fatty liver disease in mice
Ritze, Y., Bárdos, G., Claus, A., Ehrmann, V., Bergheim, I., Schwiertz, A., & Bischoff, S. C. (2014) · PLoS ONE · doi:10.1371/journal.pone.0080169 · Cited by 292
“In western societies the prevalence of NAFLD increased to 20– 30% within the general population, in the last years [9,10].”
BackgroundHistological assessment of non‐alcoholic fatty liver disease
Hübscher, S. G. (2006) · Histopathology · doi:10.1111/j.1365-2559.2006.02416.x · Cited by 292
Nonalcoholic fatty liver disease: predisposing factors and the role of nutrition
Cave, M., Deaciuc, I., Mendez, C., Song, Z., Joshi-Barve, S., Barve, S., & McClain, C. (2007) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2006.12.006 · Cited by 291
Pathogenesis and management issues for non-alcoholic fatty liver disease
Duvnjak, M. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i34.4539 · Cited by 264
Allard, J. P., Aghdassi, E., Mohammed, S., Raman, M., Avand, G., Arendt, B. M., Jalali, P., Kandasamy, T., Prayitno, N., Sherman, M., et al. (2008) · Journal of Hepatology · doi:10.1016/j.jhep.2007.09.009 · Cited by 247
Bertola, A., Bonnafous, S., Anty, R., Patouraux, S., Saint-Paul, M.-C., Iannelli, A., Gugenheim, J., Barr, J., Mato, J. M., Le Marchand-Brustel, Y., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013577 · Cited by 240
“TNFa, IL6, IL1b, CXCL8 and TGFb, which are obvious actors in the pathogenesis of progressive NAFLD, are involved in hepatocytes death/apoptosis (TNFa, TGFb), neutrophil chemotaxis (CXCL8), activation of hepatic cells (TNFa, TGFb), Mallory-Denk bodies (TNFa, TGFb) and hepatic insulin resistance (TNFa, IL6, IL1b and SOC…”
BackgroundNew role of irisin in hepatocytes: the protective effect of hepatic steatosis in vitro
Park, M.-J., Kim, D.-I., Choi, J.-H., Heo, Y.-R., & Park, S.-H. (2015) · Cellular Signalling · doi:10.1016/j.cellsig.2015.04.010 · Cited by 168
Chen, X., Zhang, L., Zheng, L., & Tuo, B. (2022) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2022.5169 · Cited by 22
“presently no satisfactory therapeutic approach for NAFLd due to its uncertain pathophysiology, NAFLd therapeutics are still dependent on improving the lifestyle and changing the eating habits of individuals (11,12).”
BackgroundNash, insulin resistance and iron
MACHADO, M., & CORTEZ‐PINTO, H. (2006) · Liver International · doi:10.1111/j.1478-3231.2006.01394.x · Cited by 18
“It is now accepted that NASH is a multistep process with a prominent role for IR, where oxidative stress and cytokines retain a central role (1).”
BackgroundSelf-citation
Metadata
- Authors
- Cortez-Pinto, H., de Moura, M. C., & Day, C. P.
- Venue
- Journal of Hepatology
- Publisher
- Elsevier BV
- Published
- 2006-01
- Volume
- 44
- Issue
- 1
- Pages
- 197-208
- ISSN
- 0168-8278 (ISSN-L)
- OpenAlex
- W2088371362
- Cited by
- 194
- References
- 32
- FWCI
- 10.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.